16282370	Disease	Gene	D011471	367	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ AR @/GeneTgt$ ? [SEP] Stress kinase signaling regulates @GeneTgt$ androgen receptor @/GeneTgt$ phosphorylation , transcription , and localization . Activation of signal transduction kinase cascades is known to alter @GeneTgt$ androgen receptor @/GeneTgt$ ( @GeneTgt$ AR @/GeneTgt$ ) activity , but the molecular mechanisms are still poorly defined . Here we show that stress kinase signaling regulates Ser 650 phosphorylation and @GeneTgt$ AR @/GeneTgt$ nuclear export . In LNCaP @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells , activation of either MAPK kinase ( MKK ) 4:c-Jun N-terminal kinase ( JNK ) or MKK6:p38 signaling pathways increased Ser 650 phosphorylation , whereas pharmacologic inhibition of JNK or p38 signaling led to a reduction of @GeneTgt$ AR @/GeneTgt$ Ser 650 phosphorylation . Both p38alpha and JNK1 phosphorylated Ser 650 in vitro . Small interfering RNA-mediated knockdown of either MKK4 or MKK6 increased endogenous prostate-specific antigen ( PSA ) transcript levels , and this increase was blocked by either bicalutamide or @GeneTgt$ AR @/GeneTgt$ small interfering RNA . Stress kinase inhibition of PSA transcription is , therefore , dependent on the @GeneTgt$ AR @/GeneTgt$ . Similar experiments involving either activation or inhibition of MAPK/ERK kinase : ERK signaling had little effect on Ser 650 phosphorylation or PSA mRNA levels . Ser 650 is proximal to the DNA binding domain that contains a nuclear export signal . Mutation of Ser 650 to alanine reduced nuclear export of the @GeneTgt$ AR @/GeneTgt$ , whereas mutation of Ser 650 to the phosphomimetic amino acid aspartate restored @GeneTgt$ AR @/GeneTgt$ nuclear export . Pharmacologic inhibition of stress kinase signaling reduced wild-type @GeneTgt$ AR @/GeneTgt$ nuclear export equivalent to the S650A mutant without affecting nuclear export of the S650D mutant . Our data suggest that stress kinase signaling and nuclear export regulate @GeneTgt$ AR @/GeneTgt$ transcriptional activity .	3 3 4 4 8|4 8|4 8 8|4 4 8 8 8 8 8 4 23 21 21 21 21 16 23 23 25 23 33|25|26 33|25|26 33|26 33|25|26 30 33|27 33 33|27 30 25 23 23 38 38 42 42 42 42 23 23 48 48 48 53 52 52 53 48 56 56 53 56 61|57 61 61|57 61 56 48 69 69 65|69 65|69 69 65|69 89 89 89 77 75 75 77 77 71 77 81 81 77 83 81 83 77 88 88 77 89 92 92 89 89 89 96 102 98 96 98 98 98 89 105 105 102 111 111|104 111 111|104 111 111 105 89 116 119 116 116 119 119 123 123 119 119 126 134 128 126 131 131 128 131 131 134 137 137 142 139 142 142 142 134 134 134 146 148 148 134 151 151 148 151 156|152 156 156|152 156 151 151 134 161 162 170 165 165 162 170 170 170 170 170 173 173 170|172 170 170|172 170 178 190 178 181 179 181 181 186 186 183 178 189 190 190 192 190 196 196 196 192 196 199 200 196 190 205 202 205 205 210 210 210 210 205 212 210 216 216 216 212 205 224 220 218 220 223 218 224 226 224 229 229 226|228 226 226|228 224 243 243 235 233 235 242 242 242 242 242 233 224 242|247 247 242|247 247 243 224 252 257 256 256 256 252 257 263 258|262 262 258|262 262 263 257 267 267 267 263 269 257 271 269 275 275 275 271 257 279 280 280 288 284 284 288 284 287 284 280 288|292 292 288|292 292 288 280	Association
18565893	Disease	Gene	D008545	472	True	0	What is [EMU_PC] between @DiseaseSrc$ melanoma @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for @DiseaseSrc$ melanoma @/DiseaseSrc$ , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 166|161 161 166|161 168 175 174 174 175 168 175 179 179 175 175 183 183 175 183 183 190 189 189 190 168 190 194 194 190 194 197 168 201 201 201 197 133 206 206 208 206 213 213|209 213 213|209 213 208 213 213 221 221 220 220 221 206 225 225 225 221 225 228 235 235 235 235 235 234 235 206 239 239 239 235 239 243 243 235 243 249 248 248 249 235 249 253 253 249 253 258 258 258 253 253 249 265 264 264 265 249 265 269 269 265 269 272 265 275 275 272 206 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
18565893	Disease	Gene	D001943	472	True	0	What is [EMU_PC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of @DiseaseSrc$ breast cancer @/DiseaseSrc$ in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 72 69|72 69|72 69|72 69|72 64 64 81 81 81 81 64 85 85 85 81 52 90 90 90 95 95 90 97 95 102 102 102 102 97 105 105 97 105 109 109 105 95 112 114 114 95 114 95 135 117 120 117 122 120 127 127|123 127 127|123 127 122 127 127 135 135 134 134 131 135 139 139 139 135 139 142 149 149 149 149 149 148 149 117 149 153 153 149 153 156 156|153|154 156|153|154 156|153 156|153|154 156 164 163 163 164 135 164 168 168 164 168 171 164 171 177 176 176 177 171 177 181 181 177 177 185 185 177 185 185 192 191 191 192 171 192 196 196 192 196 199 171 203 203 203 199 135 208 208 210 208 215 215|211 215 215|211 215 210 215 215 223 223 222 222 223 208 227 227 227 223 227 230 237 237 237 237 237 236 237 208 241 241 241 237 241 244 242|244|237 242|244|237 244|237 242|244|237 244 252 251 251 252 237 252 256 256 252 256 261 261 261 256 256 252 268 267 267 268 252 268 272 272 268 272 275 268 278 278 275 208 282 290 283|287 287 283|287 287 290 290 290 282 292 290 294 292 290 295 298 298|295|296 298|295|296 298|295 298|295|296 304 304 304 290 290 309 309 309 290 312 312 309 320 317|310 317 317|310 317 320 320 320 309 324 324 324 320 328 328 328 324 282 335 335 344 337 335 344 344 342 342 339 344 344 346 344 346 347 350 346 344	Association
18565893	Disease	Gene	D011471	472	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for @DiseaseSrc$ prostate cancer @/DiseaseSrc$ , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 161 168 174 173 173 174 168 174 178 178 174 174 181 179|181|174 179|181|174 181|174 179|181|174 181 181 190 189 189 190 168 190 194 194 190 194 197 168 201 201 201 197 133 206 206 208 206 213 213|209 213 213|209 213 208 213 213 221 221 220 220 221 206 225 225 225 221 225 228 235 235 235 235 235 234 235 206 239 239 239 235 239 243 243 235 243 249 248 248 249 235 249 253 253 249 253 258 258 258 253 253 249 265 264 264 265 249 265 269 269 265 269 272 265 275 275 272 206 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
16835864	Disease	Gene	D011471	11200	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ CHEK2 @/GeneTgt$ ? [SEP] Characterization of @GeneTgt$ CHEK2 @/GeneTgt$ mutations in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . The @GeneTgt$ checkpoint kinase 2 @/GeneTgt$ ( @GeneTgt$ CHEK2 @/GeneTgt$ , also known as @GeneTgt$ CHK2 @/GeneTgt$ ) is a tumor suppressor that participates in the DNA damage-signaling pathway . It is phosphorylated and activated following DNA damage , resulting in cell cycle arrest and apoptosis . Previously , we reported germline @GeneTgt$ CHEK2 @/GeneTgt$ mutations in patients with @DiseaseSrc$ prostate cancer @/DiseaseSrc$ . In this study , we have identified two novel somatic @GeneTgt$ CHEK2 @/GeneTgt$ mutations , c.349A > G ( p. R117 G ) and c.967A > C ( p. E321 K ) , in @DiseaseSrc$ prostate tumor @/DiseaseSrc$ specimens and investigated the functions of these mutants in vivo . We have shown that most of the germline @GeneTgt$ CHEK2 @/GeneTgt$ mutations and one somatic mutation ( p. R117 G ) within FHA domain have modestly reduced @GeneTgt$ CHEK2 @/GeneTgt$ kinase activity in comparison with wild-type @GeneTgt$ CHEK2 @/GeneTgt$ while the other somatic mutation ( p. E321 K ) within the kinase domain of @GeneTgt$ CHEK2 @/GeneTgt$ totally abolished @GeneTgt$ CHEK2 @/GeneTgt$ kinase activity . Given that several clinical @GeneTgt$ CHEK2 @/GeneTgt$ mutations reside in the Forkhead-associated ( FHA ) domain , we further generated a series of missense mutations within this domain and demonstrated the requirement of an intact FHA domain for the full activation of @GeneTgt$ CHEK2 @/GeneTgt$ . Taken together , these results provide evidence that both germline and somatic @GeneTgt$ CHEK2 @/GeneTgt$ mutations identified in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ may contribute to the development of @DiseaseSrc$ prostate cancer @/DiseaseSrc$ through the reduction of @GeneTgt$ CHEK2 @/GeneTgt$ activation in response to DNA damage and/or oncogenic stress .	1 5 2|5 5 2|5 1 7 1|5|7 1|5|7 1|7 1|5|7 1 14 13|14|31 13|14|31 13|14|31 14|31 13|14|31 19 14|15 14 14|15 19 23 14 25 20|23 23 20|23 14 31 31 31 31 33 31 38 38 38 38 33 31 45 45 45 45 45 50 50 47 45 45 56 56 56 52 56 56 45 63 63 63 63 67 67|64 67 67|64 63 69 67 71 69|71 69|71 69|71 69|71 63 79 79 83 83 83 83 83 89 89 89 86|89 89 86|89 83 83 83 91 92 97 97 97 93 97 91 91 106 106 106 106 106 100 106 91 113 108|113 108|113 113 108|113 91 83 83 117 115 120 120 117 122 115 83 128 128 128 151 151 136 136 136 133|136 136 133|136 130 130 140 140 130 144 144 144 140 144 148 148 140 151 151 128 150|155 155 150|155 155 151 157 151 160 160 157 157 157 180 166 166 166 180 170 170 170 166 170 175 175 175 166 177 173|175 175 173|175 180 151 184|176 184 184|176 184 180 128 198 198 197 197 194|197 197 194|197 198 209 205 205 205 205 205 205 198 209 209 209 209 211 209 214 214 211 217 217 211 209 209 221 219 226 226 226 226 221 230 230 230 221 232 230 230 230 209 242 237 242 241 242 242 242 252 246 252 246 251 248|251 251 248|251 246 243 254 252|254 252|254 252|254 252|254 258 242 261 261 258 263 261|263|259 261|263|259 261|263 261|263|259 268 268 261 272 264|272 272 264|272 268 274 268 277 277 274 277 280 277 242	Association
17487399	Disease	Gene	D030321	7490	True	0	What is [EMU_PC] between @DiseaseSrc$ Denys-Drash syndrome @/DiseaseSrc$ and @GeneTgt$ WT1 @/GeneTgt$ ? [SEP] VEGF transcription and mRNA stability are altered by @GeneTgt$ WT1 @/GeneTgt$ not DDS(R384W ) expression in LNCaP cells . To identify physiologically relevant @GeneTgt$ WT1 @/GeneTgt$ transcriptional target genes in prostate cancer cells , we have established stably transfected LNCaP cell lines expressing either @GeneTgt$ WT1(A @/GeneTgt$ ) , its mutant counterpart DDS(R384W ) , or vector control . Microarray analyses of these cells revealed that vascular endothelial growth factor ( VEGF ) was differentially expressed in the engineered lines . Regulation of VEGF by @GeneTgt$ WT1 @/GeneTgt$ likely contributes to kidney angiogenesis during development and @GeneTgt$ WT1 @/GeneTgt$ mutants such as DDS(R384W ) are associated with the @DiseaseSrc$ Denys-Drash syndrome @/DiseaseSrc$ ( DDS ) , characterized by renal abnormalities . Recent mechanistic studies have demonstrated that the @GeneTgt$ WT1(A @/GeneTgt$ ) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs . However , regulation of VEGF is complex , involving both transcriptional and post-transcriptional processes . This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP , DDS-LNCaP , or V-LNCaP prostate cancer cells . The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog , R1881 . One possible explanation for these results was that @GeneTgt$ DDS-WT1 @/GeneTgt$ stabilized VEGF mRNA so that it accumulated to higher levels . This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D ( Act D ) and then measuring VEGF mRNA levels by quantitative real-time PCR . The combined effects of @GeneTgt$ WT1 @/GeneTgt$ or DDS(R384W ) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells . The results indicated that @GeneTgt$ DDS-WT1 @/GeneTgt$ is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP prostate cancer cells . However our observations are also consistent with wild-type @GeneTgt$ WT1(A @/GeneTgt$ ) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone . These studies of VEGF regulation by @GeneTgt$ WT1 @/GeneTgt$ and dysregulation by DDS(R384W ) suggest an important role for @GeneTgt$ WT1 @/GeneTgt$ in both normal and tumor-related angiogenesis .	2 7 2 5 2 7 7 12 8|12 12 8|12 12 7 12 7 17 17 14 7 21 36 23 28 28|23 28 28|23 28 28 21 32 32 32 28 36 36 36 36 38 41 41 41 36 41 44 42 42 42 41 36 51 51 51 36 51 36 36 56 36 36 61 65 64 64 61 65 76 70 70 70 76 72 70 72 76 76 65 80 80 80 76 65 89 84 82 86 82|85 82 82|85 89 89 92 92 89 94 92 94 94 94 94 94 101 99 98 98 104 89 107 107 107|104 107|104 107|104 107|104 111 107 111 107 107 117 117 114 89 124 124 126 126 126 133 132 132|128 132 132|128 132 133 126 135 136 133 133 139 133 142 142 139 126 151 151 151 149 147 151 151 151 151 155 158 155 155 153 151 161 162 162 164 162 166 164 166 169 170 166 172 164 174 175 172 179 178 179 172 179 179 181 181 181 187 187 179 162 190 195 193 193 190 195 195 199 199 199 195 208 208 204 204 201 207 207 201 199 212 212 212 208 216 216 216 212 216 216 195 222 222 226 225 225 222 226 230 227|230 230 227|230 226 232 230 236 236 236 230 239 239 236 226 243 245 245 245 247 245 250 250 247 253 253 250 256 256 253 256 245 260 245 262 263 260 267 267 267 260 245 271 271 281 273 271|272 271 271|272 273 273 273 273 273 281 281 286 286 286 286 281 281 291 291 291 281 296 294 296 296 291 281 300 301 301 306 306|302 306 306|302 306 301 308 306 310 308 308 308 314 312 319 319 319 319 312 301 327 324 327 327 327 327 330 330 329|327 327 329|327 330 327 335 338 335 335 333 342 341 342 338 345 345 333 347 345 327 351 363 354 354 351 356 351|355 351 351|355 356 356 361 359 351 363 366 366 363 368 366 366 366 375 372 375 372 372 366 363	Association
17487399	Disease	Gene	D011471	7490	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ WT1 @/GeneTgt$ ? [SEP] VEGF transcription and mRNA stability are altered by @GeneTgt$ WT1 @/GeneTgt$ not DDS(R384W ) expression in LNCaP cells . To identify physiologically relevant @GeneTgt$ WT1 @/GeneTgt$ transcriptional target genes in @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells , we have established stably transfected LNCaP cell lines expressing either @GeneTgt$ WT1(A @/GeneTgt$ ) , its mutant counterpart DDS(R384W ) , or vector control . Microarray analyses of these cells revealed that vascular endothelial growth factor ( VEGF ) was differentially expressed in the engineered lines . Regulation of VEGF by @GeneTgt$ WT1 @/GeneTgt$ likely contributes to kidney angiogenesis during development and @GeneTgt$ WT1 @/GeneTgt$ mutants such as DDS(R384W ) are associated with the Denys-Drash syndrome ( DDS ) , characterized by renal abnormalities . Recent mechanistic studies have demonstrated that the @GeneTgt$ WT1(A @/GeneTgt$ ) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs . However , regulation of VEGF is complex , involving both transcriptional and post-transcriptional processes . This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP , DDS-LNCaP , or V-LNCaP @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells . The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog , R1881 . One possible explanation for these results was that @GeneTgt$ DDS-WT1 @/GeneTgt$ stabilized VEGF mRNA so that it accumulated to higher levels . This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D ( Act D ) and then measuring VEGF mRNA levels by quantitative real-time PCR . The combined effects of @GeneTgt$ WT1 @/GeneTgt$ or DDS(R384W ) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells . The results indicated that @GeneTgt$ DDS-WT1 @/GeneTgt$ is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP @DiseaseSrc$ prostate cancer @/DiseaseSrc$ cells . However our observations are also consistent with wild-type @GeneTgt$ WT1(A @/GeneTgt$ ) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone . These studies of VEGF regulation by @GeneTgt$ WT1 @/GeneTgt$ and dysregulation by DDS(R384W ) suggest an important role for @GeneTgt$ WT1 @/GeneTgt$ in both normal and tumor-related angiogenesis .	2 7 2 5 2 7 7 12 8|12 12 8|12 12 7 12 7 17 17 14 7 21 37 23 28 28|23 28 28|23 28 28 21 33 28|33 28|33 33 28|33 28 37 37 37 37 39 42 42 42 37 42 45 43|41 43 43|41 42 37 52 52 52 37 52 37 37 57 37 37 63 67 66 66 63 67 78 72 72 72 78 74 72 74 78 78 67 82 82 82 78 67 91 86 84 88 84|87 84 84|87 91 91 94 94 91 96 94 96 96 96 96 96 103 101 100 100 106 91 110 110 110 106 112 110 112 110 110 118 118 115 91 124 124 126 126 126 133 132 132|128 132 132|128 132 133 126 135 136 133 133 139 133 142 142 139 126 151 151 151 149 147 151 151 151 151 155 158 155 155 153 151 161 162 162 164 162 166 164 166 169 170 166 172 164 174 175 172 179 178 179 172 179 179 181 181 181 184|188 184|188 188 184|188 179 162 192 197 195 195 192 197 197 201 201 201 197 210 210 206 206 203 209 209 203 201 214 214 214 210 218 218 218 214 218 218 197 224 224 228 227 227 224 228 232 229|232 232 229|232 228 234 232 238 238 238 232 241 241 238 228 245 247 247 247 249 247 252 252 249 255 255 252 258 258 255 258 247 262 247 264 265 262 269 269 269 262 247 273 273 283 275 273|274 273 273|274 275 275 275 275 275 283 283 288 288 288 288 283 283 293 293 293 283 298 296 298 298 293 283 302 303 303 308 308|304 308 308|304 308 303 310 308 312 310 310 310 316 314 322 322 317|322 317|322 322 317|322 314 303 331 328 331 331 331 331 334 334 333|331 331 333|331 334 331 339 342 339 339 337 346 345 346 342 349 349 337 351 349 331 355 367 358 358 355 360 355|359 355 355|359 360 360 365 363 355 367 370 370 367 372 370 370 370 379 376 379 376 376 370 367	Association
15146458	Disease	Gene	D011471	23520	True	0	What is [EMU_PC] between @DiseaseSrc$ prostate cancer @/DiseaseSrc$ and @GeneTgt$ pp32r1 @/GeneTgt$ ? [SEP] Identification of a functional mutation in @GeneTgt$ pp32r1 @/GeneTgt$ ( @GeneTgt$ ANP32C @/GeneTgt$ ) . No mutations or polymorphisms have previously been reported in @GeneTgt$ pp32r1 @/GeneTgt$ ( @GeneTgt$ ANP32C @/GeneTgt$ ; GenBank : AF008216.1 ) . @GeneTgt$ pp32r1 @/GeneTgt$ is part of the highly conserved ANP32 family , some of whose members are associated with control of histone acetylation , mRNA stability , and specialized forms of apoptosis . Although 87.6 % identical at the protein level , @GeneTgt$ pp32r1 @/GeneTgt$ is functionally distinct from pp32 ( ANP32A ) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays . The present study found that @GeneTgt$ pp32r1 @/GeneTgt$ expression levels vary among human tumor cell lines , with the highest levels found in @DiseaseSrc$ prostatic adenocarcinoma @/DiseaseSrc$ cell lines . @GeneTgt$ pp32r1 @/GeneTgt$ also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions , human fibroblast cell lines , and several carcinoma cell lines . PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci , but additionally contain a g.4870T > C transversion mutation . The mutation results in a p. Tyr140His substitution , which lies in a functionally important region of the molecule . In the PC-3 @DiseaseSrc$ prostate cancer @/DiseaseSrc$ line , the mutation is either homozygous , or hemizygous accompanied by loss of heterozygosity . ACHN cells stably transfected with @GeneTgt$ pp32r1 @/GeneTgt$ containing this mutation showed a markedly increased rate of growth . The @GeneTgt$ pp32r1 @/GeneTgt$ mutation could thus be causally associated with the neoplastic growth properties of PC-3 , and be of potential clinical significance .	1 5 5 5 1 7 5|6 5 5|6 10 8|7 7 8|7 10 1 17 23 17 17 23 23 23 23 28 24|28 28 24|28 28 23|26 23 23|26 28 28 31 31 28 23 37|41 41 37|41 41 41 47 47 45 47 47 41 47 54 54 52 54 54 41 56 54 59 59 56 59 62 59 54 54 66 54 68 66 41 74 73 74 84 78 78 78 74 84 79|84 84 79|84 84 84 84 86 84 88 86 88 92 92 84 94 92 94 100 100 97 100 95 92 103 92 107 107 105 103 84 112 112 113 113 119 118|114 118 118|114 118 119 113 124 124 124 124 119 124 129 129 129 124 129 136 136|130 136|130 136 136|130 136 130 113 139|143 143 139|143 143 143 146 146 143 149 149 146 149 152 149 158 158 158 158 158 149 143 163 163 163 143 163 143 169 169 169 143 143 176 176 176 176 178 178 178 181 181 178 184 184 181 178 178 188 178 190 188 190 194 194 190 178 197 198 198 203 203 203 201 198 203 206 203 211 211 210 211 206 214 214 211 198 222 222 222 218|222 218|222 222 218|222 228 222 225 228 228 228 228 228 228 228 228 234 232 236 234 228 240 249 242 240 244 242|243 242 242|243 244 248 246 249 253 252 253 249 255 253 249 261 258|261 261 258|261 266 266 266 266 266 266 271 271 271 271 266 273 271 266 266 280 280 280 280 266 266	Association
